Search Results
Results found for "Chris Evans"
- How to Avoid the Most Common Gaps in Your Biotech Pitch
them who it’s for, why it matters, and what makes it different, then they start mentally moving on, even The Most Common Mistakes in Biotech Pitches Even the most brilliant science can get lost in a poor pitch structure, sequencing, and focus. 👉 Here are the most common gaps we see in early-stage biotech pitches, even
- The Chemistry of Confidence: Aha Moments That Shape Scientific Careers
, her early decisions were based on curiosity, instinct, and a surprising love of cooking (yes, she even
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
activity in an orthosteric site-independent manner to compounds with therapeutic potential that have even antagonist, partial agonist, and biased agonist outcomes in various primary and clonal cell systems, with even
- Why “Displacement” Misleads You: Allosteric Binding Demystified
Kenakin shows how even small cooperativity values (like α = 0.1) cap the shift in signal . This framework explains partial signals , paradoxical responses , and the persistence of radiolabel even
- Scientific Isolation: The Real Reason Early Biotechs Lose Traction
positioning document (“Why This Matters Now”) Predictable touchpoints with partners and investors, even decisions locked vs flexible timeline components Good looks like: The team knows what happens next, even
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
How It Worked BMS funded the research, salary, and even tuition UConn accepted the research done in the
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
🔹 Elevate your strategy → Building clarity in GPCR drug discovery Even the strongest GPCR programs
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue Even perfect receptor pharmacology fails if target-site exposure is insufficient or transient .
- Understanding the Journey: Catherine Demery's Path to Addiction Science
Catherine’s methodical retention of those skills later gave her a solid foundation in her academic work, even Technical discipline is transferable—even across research cultures.
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
In the full lecture, you will learn how to extract affinity even in this dual-behavior scenario: Focus Even when maximal responses are altered, affinity constants remain extractable from correctly chosen
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Kenakin reminds us: “Allostery will seek you—even if you don’t seek it.” How CRO Communication Impacts GPCR Drug Development Success Even the best science falters without operational
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
GPCRs in the Background, But Always Present Even though his primary focus wasn’t GPCRs themselves, Serafini
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
advantage of many successful drugs: they bind tightly or covalently , making target coverage durable even Even if your drug reaches its target, the effect it leaves behind rewrites the PK/PD playbook.
- From Snapshots to Predictions: Why Mechanism of Action Matters
danger: if you can’t tell how a drug is working, every downstream decision—SAR, lead optimization, even Garbage In, Garbage Out Even the best models can only work with the data they’re fed.
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Learn to leverage restricted diffusion and rebinding to create drugs with longer therapeutic coverage, even distinguish between active and inactive ligands, paving the way for computational ligand discovery even
- Pharmacology at Your Fingertips: Terry’s Corner Launches
Because even the best data means nothing without structure. That’s the Lego Bucket Problem.
- Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools
detecting endogenous GPCRs With pHSense™, scientists can finally track GPCR internalization in real time—even
- The One Reason Why Biotech Startups Fail More Often Than They Should
Additional data feels like risk reduction, even when it does not change the strategic picture. Without it, even strong science slowly loses direction. 👉 Understanding why biotech startups fail is
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Terry Kenakin’s session examines not just how binding works, but why so many datasets mislead even Even the familiar saturation experiment hides traps.
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
How enzyme behavior introduces nonlinear risk even in receptor-driven programs. Kenakin showed how the same agonist can behave as near-full, partial, or even silent depending on receptor
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Most drugs don’t fail at the receptor level—they fail before they even reach it. Even the most elegant GPCR ligand can fail if it never reaches its receptor.
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
reasons why researchers typically require years to uncover the mechanisms of disease before they can even
- Serotonin Receptor 5-HT2A Regulates TrkB Receptor Function in Heteroreceptor Complexes
Heterodimerization decreased TrkB autophosphorylation, preventing its activation with agonist 7,8-DHF, even
- C5aR2 receptor: The genomic twin of the flamboyant C5aR1
Currently, the exact function of the C5aR2 is actively debated in the context of C5aR1, even though both
- Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair
Chronic human HF is characterized by several important neurohormonal perturbations, emanating from both
- Conjugation Strategies for Probe Development
NHS esters are not very stable even in aqueous environment but they only need a slightly basic medium
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
therapeutic window ✅ Examples of how rebinding in dense receptor environments amplifies target occupancy, even
- Asking Better Questions in Science: A Practical Guide for Emerging Researchers
Yet one well-timed question can unlock clarity, accelerate a stalled project, or even spark a collaboration
- How Fast Does a Drug Work?
a ligand binds (k₁) and how long it stays bound (k₂) can alter therapeutic profiles dramatically, even
























